It has been a turbulent time for the pharmaceutical industry – especially in regard to the clinical trial sector. From reduced investment, to a lack of public trust in the industry, it has been ...
Persistent recruitment delays, high dropout rates, and missed timelines continue to slow global clinical trials, while data show that sub-Saharan Africa offers a largely untapped opportunity with ...
Daedalus, Vol. 154, No. 2, The Ethics of Social Research: Perspectives from the Study of the Middle East & North Africa (Spring 2025), pp. 157-168 (12 pages) As the Middle East and North Africa (MENA) ...
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Earlier detection of cancer offers an opportunity to ...
A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...
6don MSNOpinion
Why you should be pleased we run trials on nudges, even if you don't like nudges (or trials)
Last year, we ran a randomized controlled trial working with frontline workers in the homelessness sector, which aimed to ...
“Well, we don’t have as much evidence as we would like on steroid use during pregnancy,” the obstetrician warned my co-author, Natalia Emanuel, as she wrote a prescription for inhaled corticosteroids ...
Clinical Trials Arena on MSN
Utilising real-world data to overcome challenges in rare disease research
Synthetic control arms may help tackle the unique complexities, but key challenges such as data access and standardisation remain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback